MTOR and breast cancer: Furthermore, immunohistochemistry and immunofluorescence experiments verified that LHX2 promoted the expressions of infiltrating T cells and CD4 + T cells in breast cancer, and a Western blot assay demonstrated that LHX2 activates the PI3K/AKT/mTOR pathway and apoptosis pathway.